GC Cell has initiated first patient dosing in a Phase 1 clinical trial of GCC2005, a novel CD5 CAR-NK cell therapy targeting relapsed or refractory NK and T-cell malignancies, addressing a significant unmet need in aggressive lymphomas.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.